BBIO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
243.7M
+25.3%
194.5M
+26.2%
154.2M
+27.7%
120.7M
+9.2%
110.6M
Cost of Revenue
15.0M
+51.4%
9.9M
+22.6%
8.1M
+23.5%
6.6M
+79.7%
3.7M
Gross Profit
228.6M
+23.9%
184.6M
+26.4%
146.1M
+28.0%
114.1M
+6.8%
106.9M
Operating Expenses
335.7M
+15.5%
290.5M
+1.7%
285.6M
+10.1%
259.3M
+7.5%
241.2M
R&D
149.4M
+18.0%
126.6M
+8.8%
116.4M
+3.1%
112.9M
+1.5%
111.2M
SG&A
186.3M
+13.6%
163.9M
+3.7%
158.1M
+14.9%
137.6M
+6.6%
129.2M
Operating Income
-107079000
-1.1%
-105956000
+24.1%
-139562000
+3.9%
-145199000
-8.1%
-134278000
EBITDA
-106026000
-1.2%
-104770000
+17.5%
-126996000
+5.9%
-134960000
-2.1%
-132156000
Net Income
-155891000
+6.4%
-166555000
+14.4%
-194635000
-5.2%
-184937000
-0.6%
-183758000
EPS (Basic)
$-0.78
+7.1%
$-0.84
+16.0%
$-1.00
-5.3%
$-0.95
+0.0%
$-0.95
EPS (Diluted)
$-0.78
+7.1%
$-0.84
+16.0%
$-1.00
-5.3%
$-0.95
+0.0%
$-0.95
Shares (Diluted)
195.8M
+0.5%
194.8M
+0.6%
193.6M
+0.9%
191.9M
+0.7%
190.5M
BridgeBio Pharma (BBIO) โ€” Financials